Common diabetes drug may shield hearts during chemo
NCT ID NCT06491680
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study tests whether dapagliflozin, a drug used for diabetes, can prevent heart damage caused by anthracycline chemotherapy in breast cancer patients. Forty women with breast cancer will take dapagliflozin daily alongside their chemo. Researchers will measure heart function and blood markers to see if the drug offers protection.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
dapagliflozin (a diabetes drug)
What this could lead to
If it works, this could offer a simple way to prevent heart damage during breast cancer chemotherapy, improving long-term heart health.
What could go wrong
This is a small, early-phase trial with only 40 participants, so results may not apply to everyone. The drug may not provide significant heart protection.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Al demerdash hospital at oncology departement
RECRUITINGCairo, Cairo Governorate, 202, Egypt
Contact Phone: •••-•••-•••• Email: •••••@•••••